2023-08-08 04:32:15 ET
- As of August 3, RegeneRx Biopharmaceuticals ( OTCQB:RGRX ) received consents from 51.7% stockholders in favor of the proposed reverse stock split, which is a prerequisite to allowing the company to suspend its public reporting obligations and become a non-reporting, privately held company.
-
J.J. Finkelstein, CEO, commented, "We thank our stockholders for voting in favor of the proposed reverse stock split. We expect to effect a 1-for-100 reverse split in our outstanding shares of Common Stock on or about August 14, 2023. Promptly thereafter, we expect to file the requisite Forms 15 to suspend our continued obligations to file reports with the SEC pursuant to the Securities Exchange Act of 1934, as amended."
For further details see:
RegeneRx receives stockholder approval for reverse stock split